Background: Identifying markers for increased risk of cognitive change and early Alzheimer's disease (AD) is key to enhancing the effectiveness of treatments. Changes in instrumental activities of daily living, including the complex task of driving, may serve as potential markers to identify older adults at risk of cognitive decline. This study evaluates driving behaviors and associated physiological signals in older adults with and without elevated brain amyloid burden.
Method: Video and physiological data from 21 amyloid positive and 21 amyloid negative consensus diagnosed cognitively normal participants over the age of 65 who participated in the University of Michigan's Driving and Physiological Responses study were analyzed. Amyloid positivity was determined based on the PET centiloid scale. All drivers completed the same fixed course route. Road- and driver-view videos of each participant were annotated to mark 40 key road events and driving behaviors, such as right turns and looking at the rear-view mirror. Heart rate (HR) and electrodermal activity (EDA) data collected through an Empatica E4 watch were analyzed for each road/driving event (e.g., average HR during freeway entrance). Independent sample t-tests with α's = 0.05 were used to look for differences between amyloid positive and negative groups.
Result: HR responses to intersections without signs and freeway entrance ramps were consistently higher among amyloid positive drivers compared to amyloid negative drivers (p's<0.05). Furthermore, amyloid positive drivers showed a pattern of lower EDA responses to freeway exit ramps than amyloid negative drivers (p<0.05).
Conclusion: Cognitively normal amyloid positive older drivers demonstrated consistently higher HR and lower EDA in key driving situations compared to their amyloid negative peers. Findings suggest physiological responses of older drivers under different driving conditions may represent markers for identifying those individuals at higher risk of future cognitive decline. These results can be used to build an accurate and generalizable Machine Learning-based AD diagnostic tool to detect early-stage AD in drivers.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1002/alz.089613 | DOI Listing |
Spinal Cord
January 2025
McKnight Brain Institute, University of Florida, Gainesville, FL, USA.
Study Design: Experimental Animal Study.
Objective: To continue validating an antibody which targets an epitope of neurofilament light chain (NF-L) only available during neurodegeneration and to utilize the antibody to describe the pattern of axonal degeneration 10 days post-unilateral C4 contusion in the rat.
Setting: University of Florida laboratory in Gainesville, USA.
Neurobiol Aging
December 2024
Vanderbilt Memory and Alzheimer's Center, Vanderbilt University Medical Center, Nashville, TN, USA; Pharmacology Department, Vanderbilt University Medical Center, Nashville, TN, USA; Department of Neurology, Vanderbilt University Medical Center, Nashville, TN, USA; Epidemiology Doctoral Program, School of Medicine, Vanderbilt University, Nashville, TN, USA; Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA. Electronic address:
We have identified FLT1 as a protein that changes during Alzheimer's disease (AD) whereby higher brain protein levels are associated with more amyloid, more tau, and faster longitudinal cognitive decline. Given FLT1's role in angiogenesis and immune activation, we hypothesized that FLT1 is upregulated in response to amyloid pathology, driving a vascular-immune cascade resulting in neurodegeneration and cognitive decline. We sought to determine (1) if in vivo FLT1 levels (CSF and plasma) associate with biomarkers of AD neuropathology or differ between diagnostic staging in an aged cohort enriched for early disease, and (2) whether FLT1 expression interacts with amyloid on downstream outcomes, such as phosphorylated tau levels and cognitive performance.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
The Second Affiliated Hospital of Chongqing Medical University, Chongqing, Chong Qing, China.
Background: Alzheimer's disease (AD) frequently coexists with cerebral small vessel disease (CSVD) is common in the aging population, yet the underlying mechanisms are not yet fully understood. Both long-term blood pressure variability (BPV) and plasma neurofilament light (PNFL) were identified as potential biomarkers for AD and CSVD. This study aims to understand the mechanisms of comorbidity between AD and CSVD by investigating the associations among BPV, PNFL, and comorbidity.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Brunel University London, London, United Kingdom.
Background: Psychosis occurs in 30-40% of individuals with AD. New insights into disease mechanisms may lead to novel pharmacological targets and treatments. Previous studies have focused on bulk tissue analysis with limited results.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Rush Alzheimer's Disease Center, Chicago, IL, USA.
Background: The recent approval of two anti-amyloid antibodies, Aducanamab and Lecanamab, have set the stage for the next generation of anti-amyloid treatments. Despite the capability of these treatments to lower Aβ brain levels, there is thus far limited clinical efficacy on cognitive outcomes. Because eligibility for treatment includes individuals with MCI or mild dementia, that often harbor mixed pathologies, the cognitive impact of other brain pathologies may be important.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!